| Advice Pool |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > News and Society > Politics > Heading For a European Constitution (4) |
|
Advice Pool - Heading For a European Constitution (4)
Technical Analysis is widely used in the area of investment. It provides a mechanism in which you -– as an According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product investor -– are able to (self) analyse the price development of a certain investment object, without havi ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ng to bother about fundamental knowledge. The technical analyst is not influenced by fundamental discussi lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ons, but keeps a tight focus on a certain movement, tendency or ... a trend. A trend is very important, be here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ause it is real. A trend is visible and you cannot deny it. Take for instance the growth of a population a d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro nd the growth of the life expectation of human beings. But also the trend related to the previous one in w ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc hich relatively less people will participate in the National Production, which increases the cost of distr easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi buting overall income (pensions). All trends you cannot deny. The technique of technical analysis -– whi nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ch is more that just signalling a trend -- could also be used in a completely different environment. In po and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ litics for example, where you are to analyse the (historical) development of the European Nations. Accord ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ng to a study that was published in the Spanish tabloid 20 minutes, the European map gained 22 countries o ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ver the last hundred years. (www.20minutos.es /noticia/127579/0/mapa/europeo/siglo/). In 1906 there were 2 dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod 2 European Nations, in 1956 this number increase to 34 and the number has already risen to 46 (or 47 if Tu cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin rkey is included). Currently Montenegro is preparing for its independence, we do not know whether they wi tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen l succeed in the attempt, but the direction is clear. In Spain itself, the independence discussions are bo t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel iling too. And with a technical analysis view on the whole issue, you might expect that Spain will no long ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust er exist as one country. Technical speaking, there is a tendency that states over a longer period get inde y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products endent. Even if it is a speculation, if you would bet with a technical viewpoint you should bet on a Spain . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de that will get divided. Results from the past however, do not predict future developments. We shouldn’t m elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip erely extrapolate the past. And, We also shouldn’t forget that there is another trend... © 2006 Hans Boo tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Internet Job Boards: What Most People Do Not Consider The Don'ts Of Internet Marketing-What Not To Do Home Internet Based Business Opportunity
|